Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)

Market Cap	21.92B
Revenue (ttm)	4.74B
Net Income (ttm)	935.80M
Shares Out	2.23B
EPS (ttm)	0.42
PE Ratio	23.53
Forward PE	24.89
Dividend	0.27 (2.74%)
Ex-Dividend Date	Jun 10, 2025

Volume	12,607,290
Average Volume	9,236,250
Open	9.87
Previous Close	9.84
Day's Range	9.77 - 9.88
52-Week Range	9.77 - 14.74
Beta	0.12
RSI	23.43
Earnings Date	Apr 20, 2026

About SHE:301301

Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. The company offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; urso...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3,184
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301301

Financial Performance

In 2024, SHE:301301's revenue was 5.76 billion, an increase of 19.38% compared to the previous year's 4.82 billion. Earnings were 1.40 billion, an increase of 48.88%.